Search Results

You are looking at 101 - 110 of 488 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Paul F. Engstrom

2002, the NCCN panel advocated 5-fluorouracil (5-FU)/leucovorin adjuvant therapy for stage III or node-positive disease and 5-FU leucovorin with or without irinotecan (IFL) as first-line therapy for metastatic disease. Second-line therapies for

Full access

Margaret A. Tempero

pancreatic cancer, 80% of patients are diagnosed with advanced unresectable disease; 80% experience relapse after resection and adjuvant therapy; and median overall survival (OS) of patients with untreated metastatic disease is only 3 months. The “cure rate

Full access

Eric Jonasch

in Oncology (NCCN Guidelines) for Kidney Cancer. Adjuvant Therapy Three trials have been conducted in the adjuvant setting, 2 of which (ASSURE and PROTECT) showed negative results for adjuvant sunitinib, sorafenib, and pazopanib. A third trial

Full access

Srinivas K. Tantravahi, and Theresa L. Werner

pathologically staged as FIGO stage IA (pT1a pN0 Mx). She received no adjuvant therapy. She returned 3 months later with recurrent vaginal bleeding. A 2-cm friable mass was visualized at the apex of the vaginal cuff on pelvic examination and was resected

Full access

Harold J. Burstein

percentage. Of course, a few caveats are warranted. The bulk of these reports are derived from studies of women taking adjuvant therapy for hormone receptor-positive breast cancer. Such patients often have a favorable prognosis and might reasonably be

Full access

Prajnan Das, Norio Fukami, and Jaffer A. Ajani

. 29. Gunderson LL Sosin H . Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy . Int J Radiat Oncol Biol Phys 1982 ; 8 : 1

Full access

Michelle T. Ashworth and Adil Daud

and MEK inhibitors, and effective adjuvant therapies can be expected to increase the impact of accurate staging with SLNB on overall survival. At the time of metastasis to lymph nodes in 2002, the patient was treated with complete lymphadenectomy

Full access

Kathleen Harnden and Kimberly Blackwell

recent prospective trial to date evaluating zoledronic acid in addition to standard adjuvant therapy in ESBC. 21 At the final efficacy analysis after a median follow-up Table 1 Characteristics of Published Phase III Trials With Zoledronic Acid

Full access

Joleen M. Hubbard and Axel Grothey

% of patients undergoing total colectomy will have 5 or more bowel movements per day, and 30% will have issues with fecal incontinence. 34 , 35 Adjuvant Therapy for Stage II and III Colon Cancer Patients with high-risk stage II and III disease

Full access

Clayton A. Smith and Lisa A. Kachnic

improve 10-year OS compared with observation (51.8% vs 48.4%; P =.32). 13 Although early analysis demonstrated a DFS benefit of adjuvant therapy for patients with ypT0–2 (hazard ratio [HR], 0.64; 95% CI, 0.45–0.91; P =.13), this benefit was not observed